Thermo Fisher Scientific vs Medpace: Which Stock Could Rally?
Thermo Fisher Scientific fell -9.2% during the past Day. You may be tempted to buy more, or may want to reduce your exposure. But there is an entirely different perspective you might be missing. Is there a better alternative? Turns out, its peer Medpace gives you more. Medpace (MEDP) stock offers superior revenue growth across key periods, better profitability, and relatively lower valuation vs Thermo Fisher Scientific (TMO) stock, suggesting you may be better off investing in MEDP
- MEDP’s quarterly revenue growth was 32.0%, vs. TMO’s 7.2%.
- In addition, its Last 12 Months revenue growth came in at 20.0%, ahead of TMO’s 3.9%.
- MEDP leads on profitability over both periods – LTM margin of 21.1% and 3-year average of 20.1%.
These differences become even clearer when you look at the financials side by side. The table highlights how TMO’s fundamentals stack up against those of MEDP on growth, margins, momentum, and valuation multiples.
Valuation & Performance Overview
| TMO | MEDP | Preferred | |
|---|---|---|---|
| Valuation | |||
| P/EBIT Ratio | 21.5 | 20.8 | MEDP |
| Revenue Growth | |||
| Last Quarter | 7.2% | 32.0% | MEDP |
| Last 12 Months | 3.9% | 20.0% | MEDP |
| Last 3 Year Average | -0.2% | 20.3% | MEDP |
| Operating Margins | |||
| Last 12 Months | 18.2% | 21.1% | MEDP |
| Last 3 Year Average | 17.8% | 20.1% | MEDP |
| Momentum | |||
| Last 3 Year Return | -17.6% | 108.1% | MEDP |
Note: For “Last 3 Year Return” metric, preferred stock is one with higher returns unless the returns are too high (>300%) which creates risk of sell off.
- Accenture Stock: Strong Cash Flow Poised for a Re-Rating?
- CVS Health Stock Shares $24 Bil Success With Investors
- PayPal Stock Pays Out $25 Bil – Investors Take Note
- Intuit Stock Testing Price Floor – Buy Now?
- Netflix Stock Hits Key Support – Buying Opportunity?
- Veeva Systems Stock Delivers Strong Cash Yield – Upside Ahead?
See detailed fundamentals on Buy or Sell MEDP Stock and Buy or Sell TMO Stock. Below we compare market return and related metrics across years.
Historical Market Performance
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | Avg | Best | |
|---|---|---|---|---|---|---|---|---|---|
| Returns | |||||||||
| TMO Return | 44% | -17% | -3% | -2% | 12% | -11% | 12% | ||
| MEDP Return | 56% | -2% | 44% | 8% | 69% | -9% | 265% | <=== | |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 4% | 90% | ||
| Monthly Win Rates [3] | |||||||||
| TMO Win Rate | 75% | 42% | 58% | 50% | 50% | 25% | 50% | ||
| MEDP Win Rate | 67% | 58% | 75% | 33% | 67% | 75% | 62% | <=== | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | 62% | ||
| Max Drawdowns [4] | |||||||||
| TMO Max Drawdown | -6% | -27% | -22% | -5% | -25% | -20% | -17% | ||
| MEDP Max Drawdown | -5% | -40% | -18% | -7% | -17% | -26% | -19% | ||
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -7% | -9% | <=== | |
[1] Cumulative total returns since the beginning of 2021
[2] 2026 data is for the year up to 4/23/2026 (YTD)
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
No matter how good the numbers, stock investment is never a smooth ride. There is a risk you must factor in. Read MEDP Dip Buyer Analyses to see how the stock has fallen and recovered in the past.
Still not sure about TMO or MEDP? Consider portfolio approach.
The Best Investors Think In Portfolios
Stocks can jump or crash, but long-term success comes from staying invested. The right portfolio helps you ride gains and cushion single stock drops.
Beating the market consistently is hard, but the Trefis High Quality (HQ) Portfolio makes it look achievable. By selecting 30 high-conviction stocks, the HQ strategy has historically outpaced the S&P 500, S&P Mid-cap, and Russell 2000. See how this curated selection delivers superior risk-adjusted returns in our detailed performance factsheet.